Francesca Stillitano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8090121/publications.pdf

Version: 2024-02-01

46 papers

2,085 citations

³⁹⁴²⁸⁶ 19 h-index 315616 38 g-index

48 all docs

48 docs citations

48 times ranked

3315 citing authors

#	Article	IF	CITATIONS
1	Developmental Changes in Cardiomyocytes Differentiated from Human Embryonic Stem Cells: A Molecular and Electrophysiological Approach. Stem Cells, 2007, 25, 1136-1144.	1.4	348
2	Late Sodium Current Inhibition Reverses Electromechanical Dysfunction in Human Hypertrophic Cardiomyopathy. Circulation, 2013, 127, 575-584.	1.6	347
3	Molecular basis of funny current (If) in normal and failing human heart. Journal of Molecular and Cellular Cardiology, 2008, 45, 289-299.	0.9	158
4	Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nature Communications, 2015, 6, 6955.	5.8	155
5	Small Molecule-Mediated Directed Differentiation of Human Embryonic Stem Cells Toward Ventricular Cardiomyocytes. Stem Cells Translational Medicine, 2014, 3, 18-31.	1.6	141
6	Exosomal microRNA-21-5p Mediates Mesenchymal Stem Cell Paracrine Effects on Human Cardiac Tissue Contractility. Circulation Research, 2018, 122, 933-944.	2.0	129
7	Modeling susceptibility to drug-induced long QT with a panel of subject-specific induced pluripotent stem cells. ELife, 2017, 6, .	2.8	82
8	Enhanced ROS production by NADPH oxidase is correlated to changes in antioxidant enzyme activity in human heart failure. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 331-338.	1.8	76
9	Considerations for pre-clinical models and clinical trials of pluripotent stem cell-derived cardiomyocytes. Stem Cell Research and Therapy, 2014, 5, 1.	2.4	62
10	Genomic correction of familial cardiomyopathy in human engineered cardiac tissues. European Heart Journal, 2016, 37, 3282-3284.	1.0	60
11	Longâ€term treatment with ivabradine in postâ€myocardial infarcted rats counteracts fâ€channel overexpression. British Journal of Pharmacology, 2012, 165, 1457-1466.	2.7	55
12	Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H366-H373.	1.5	47
13	Effectiveness of gene delivery systems for pluripotent and differentiated cells. Molecular Therapy - Methods and Clinical Development, 2015, 2, 14067.	1.8	47
14	Functional Human Beige Adipocytes From Induced Pluripotent Stem Cells. Diabetes, 2017, 66, 1470-1478.	0.3	42
15	Chronic Atrial Fibrillation Alters the Functional Properties of I _f in the Human Atrium. Journal of Cardiovascular Electrophysiology, 2013, 24, 1391-1400.	0.8	39
16	Molecular and Functional Evidence of HCN4 and Caveolin-3 Interaction During Cardiomyocyte Differentiation from Human Embryonic Stem Cells. Stem Cells and Development, 2013, 22, 1717-1727.	1.1	34
17	Growth Factor-Induced Mobilization of Cardiac Progenitor Cells Reduces the Risk of Arrhythmias, in a Rat Model of Chronic Myocardial Infarction. PLoS ONE, 2011, 6, e17750.	1.1	31
18	Functional remodeling inÂpost-myocardial infarcted rats: focus onÂbeta-adrenoceptor subtypes. Journal of Molecular and Cellular Cardiology, 2006, 40, 258-266.	0.9	27

#	Article	IF	CITATIONS
19	Functional and transcriptomic insights into pathogenesis of R9C phospholamban mutation using human induced pluripotent stem cell-derived cardiomyocytes. Journal of Molecular and Cellular Cardiology, 2018, 119, 147-154.	0.9	25
20	Differential functional effects of two 5-HT receptor isoforms in adult cardiomyocytes. Journal of Molecular and Cellular Cardiology, 2005, 39, 335-344.	0.9	24
21	Gene editing reverses arrhythmia susceptibility in humanized PLN-R14del mice: modelling a European cardiomyopathy with global impact. Cardiovascular Research, 2022, 118, 3140-3150.	1.8	23
22	Adult human cardiac stem cell supplementation effectively increases contractile function and maturation in human engineered cardiac tissues. Stem Cell Research and Therapy, 2019, 10, 373.	2.4	17
23	Cardiac Tissue Engineering Models of Inherited and Acquired Cardiomyopathies. Methods in Molecular Biology, 2018, 1816, 145-159.	0.4	16
24	Expression of the hyperpolarization-activated current, If, in cultured adult rat ventricular cardiomyocytes and its modulation by hypertrophic factors. Pharmacological Research, 2008, 57, 100-109.	3.1	15
25	Prenatal exposure to carbon monoxide delays postnatal cardiac maturation. Laboratory Investigation, 2010, 90, 1582-1593.	1.7	14
26	Impaired Right Ventricular Calcium Cycling Is an Early Risk Factor in R14del-Phospholamban Arrhythmias. Journal of Personalized Medicine, 2021, 11, 502.	1.1	12
27	Response to Letter Regarding Article, "Late Sodium Current Inhibition Reverses Electromechanical Dysfunction in Human Hypertrophic Cardiomyopathyâ€. Circulation, 2013, 128, e157.	1.6	11
28	Electrophysiologic changes in heart failure: focus on pacemaker channelsThis article is one of a selection of papers from the NATO Advanced Research Workshop on Translational Knowledge for Heart Health (published in part 1 of a 2-part Special Issue) Canadian Journal of Physiology and Pharmacology, 2009, 87, 84-90.	0.7	10
29	Arrhythmia Mechanism and Dynamics in a Humanized Mouse Model of Inherited Cardiomyopathy Caused by Phospholamban R14del Mutation. Circulation, 2021, 144, 441-454.	1.6	10
30	The direct stimulation of Gi proteins by neuropeptide Y (NPY) in the rat left ventricle. Biochemical Pharmacology, 2002, 63, 2063-2068.	2.0	8
31	Quantification of midkine gene expression in Patella caerulea (Mollusca, Gastropoda) exposed to cadmium. Estuarine, Coastal and Shelf Science, 2007, 75, 120-124.	0.9	5
32	A micromachined force sensing apparatus and method for human engineered cardiac tissue and induced pluripotent stem cell characterization. Sensors and Actuators A: Physical, 2021, 331, 112874.	2.0	4
33	Generation of human induced pluripotent stem cell (iPSC) lines derived from five patients carrying the pathogenic phospholamban-R14del (PLN-R14del) variant and three non-carrier family members. Stem Cell Research, 2022, 60, 102737.	0.3	3
34	Preclinical animal models for testing iPSC/ESC-based heart therapy. Drug Discovery Today: Disease Models, 2012, 9, e229-e236.	1.2	2
35	Gene Transfer in Cardiomyocytes Derived from ES and iPS Cells. Methods in Molecular Biology, 2017, 1521, 183-193.	0.4	2
36	Abstract P482: Elucidating And Characterizing The Molecular Mechanistic Role Of Phospholamban L39 Stop In The Pathophysiology Of Cardiomyopathy Using Patient-derived Human Induced Pluripotent Stem Cells And Humanized Knock-in Mouse Model Systems. Circulation Research, 2021, 129, .	2.0	2

#	Article	IF	CITATIONS
37	Generation of Ventricular-Like HiPSC-Derived Cardiomyocytes and High-Quality Cell Preparations for Calcium Handling Characterization. Journal of Visualized Experiments, 2020, , .	0.2	1
38	Abstract 530: Mechanisms Underlying Phospholamban L39 Stop (PLN L39X) Cardiomyopathy. Circulation Research, 2020, 127, .	2.0	1
39	Expression and modulation of f-channels in chronic atrial fibrillation: A study in human atrium. Journal of Molecular and Cellular Cardiology, 2007, 42, S6-S7.	0.9	0
40	Molecular and functional development of cardiomyocytes differentiated from human embryonic stem cells. Journal of Molecular and Cellular Cardiology, 2007, 42, S90-S91.	0.9	0
41	5-HT2 receptors enable cardiac differentiation of mouse embryonic stem cells. Journal of Molecular and Cellular Cardiology, 2007, 42, S92.	0.9	0
42	Impact of R4496C RyR2 Mutation on Myocardial Contractility. Biophysical Journal, 2011, 100, 291a.	0.2	0
43	2525 Development of human cell-based screening assays to detect subject-specific drug-response variability. Journal of Clinical and Translational Science, 2018, 2, 9-10.	0.3	O
44	3444 Development of human engineered cardiac tissue (hECT)-based screening assay to explore cardiac contractile properties in response to pharmacological challenge with proarrhythmic drugs. Journal of Clinical and Translational Science, 2019, 3, 8-8.	0.3	0
45	3213 Unraveling the role of Phospholamban (PLN) in humans via the characterization of Induced Pluripotent Stem Cell (iPSC) Cardiomyocytes (CM) derived from carriers of a lethal PLN mutation. Journal of Clinical and Translational Science, 2019, 3, 26-26.	0.3	0
46	Abstract 142: Modeling Drug-Induced Long QT Syndrome with Patient-Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Circulation Research, 2013, 113, .	2.0	0